FDA Warns GLP-1 Maker Novo Nordisk Inc. About Failure To Properly Report Deaths And Strokes
On March 5, 2026, the FDA issued a warning letter to Nova Nordisk Inc. that stated: This Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted at your firm, Novo Nordisk Inc. (hereinafter referred to as NNI), between J[...]